GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back

Safety Profile Will Be Battleground

 
• By Andrew McConaghie
  
Entrance to FDA headquarters in Maryland
After a near-unanimous vote against approval from experts, the US FDA looks likely to reject roxadustat.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip